Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Nishant Saxena Acquires 2,600 Shares

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Nishant Saxena acquired 2,600 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average cost of $9.63 per share, with a total value of $25,038.00. Following the transaction, the insider owned 77,900 shares of the company’s stock, valued at approximately $750,177. The trade was a 3.45% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Corbus Pharmaceuticals Price Performance

Shares of NASDAQ CRBP opened at $9.76 on Thursday. The business’s 50-day moving average price is $8.84 and its two-hundred day moving average price is $9.07. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $7.12 and a one year high of $20.56. The company has a market capitalization of $182.22 million, a P/E ratio of -1.58 and a beta of 2.59.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). On average, equities analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -5.22 EPS for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Persistent Asset Partners Ltd acquired a new position in Corbus Pharmaceuticals during the fourth quarter valued at approximately $54,000. Virtu Financial LLC acquired a new stake in shares of Corbus Pharmaceuticals in the fourth quarter worth $88,000. Barclays PLC lifted its stake in shares of Corbus Pharmaceuticals by 280.0% in the fourth quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 10,874 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Corbus Pharmaceuticals during the 3rd quarter worth $129,000. Finally, Bank of America Corp DE boosted its holdings in shares of Corbus Pharmaceuticals by 53,592.3% during the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 13,934 shares during the period. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Corbus Pharmaceuticals

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Director Nishant C. Saxena purchased 2,600 CRBP shares for approximately $25,038 at an average price of $9.63, increasing his direct ownership by 3.45%. Insider buying can signal management confidence in the company’s valuation. SEC insider ownership filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, substantially above recent trading levels. The firm continues to model a return to profitability by 2030, although its estimates were lowered.
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the data showed no short position and no meaningful change, it provides little actionable signal for investors.
• Negative Sentiment: HC Wainwright cut EPS forecasts across 2026-2030, including 2026 to a loss of $6.11 per share from $4.99, 2027 to a loss of $6.83 from $5.66, and 2030 profit to $0.15 from $1.29. The revisions point to weaker near- and long-term earnings expectations despite the Buy rating.
• Negative Sentiment: CFO Sean Moran sold 12,000 shares for approximately $120,960, reducing his holdings by 12.41%. The sale may weigh on sentiment, although insider transactions do not necessarily indicate a change in the company’s outlook. CFO stock sale report
• Negative Sentiment: Corbus recently reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate, reinforcing concerns about continued cash burn and execution risk for its clinical-stage pipeline.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CRBP shares. Guggenheim reiterated a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Jefferies Financial Group dropped their price target on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Wedbush cut their price target on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 27th. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Oppenheimer decreased their price objective on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.12.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.